Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Solskin Caribou Biosciences, Inc. (NASDAQ:CRBU) is gearing up to present initial dose expansion data from its ongoing phase 1 ANTLER study. This particular early-stage study uses CB-010 for the treatment of patients with 2nd-line relapsed or refractory large B cell lymphoma [r/r LBCL]. Positive data from the dose-escalation portion of the study was already released. What investors can look forward to regarding the advancement of this program would be two catalysts in particular. The first catalyst would be ...